Kenneth Jay Cohen MD

Oncology•Baltimore, MD

Neuro-Oncology

Professor of Oncology and Pediatrics, Johns Hopkins University School of Medicine; Director, Pediatric Neuro-Oncology; Clinical Director Pediatric Oncology; Director, Strategic Partnerships, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Join to View Full Profile

1800 Orleans StreetBloomberg 11NBaltimore, MD 21287
Phone+1 410-955-8751
Fax+1 410-614-1802

Summary

Dr. Kenneth Cohen is the Clinical Director of Pediatric Oncology and Director of Pediatric Neuro-Oncology at Johns Hopkins in Baltimore, MD. He received his medical degree from SUNY Upstate Medical University and has been in practice 30 years. He specializes in pediatric neuro-oncology and general pediatric oncology. He has more than 80 publications and over 500 citings.

Education & Training

Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1991 - 1994
University of ColoradoChief Residency, Pediatrics, 1990 - 1991
University of ColoradoResidency, Pediatrics, 1987 - 1990
SUNY Upstate Medical UniversityClass of 1987

Certifications & Licensure

MD State Medical License 1991 - 2026
PA State Medical License 2024 - 2026
FL State Medical License 2016 - 2018
CO State Medical License 1990 - 1991
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 May 23
ACTIVE_NOT_RECRUITING
PHASE3
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
ACTIVE_NOT_RECRUITING
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
ACTIVE_NOT_RECRUITING
PHASE3
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01
Terminated
Phase 2
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
Completed
Phase 2
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
COMPLETED
PHASE2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Start of enrollment: 2014 Mar 05
Recruiting
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma Start of enrollment: 2017 Apr 04
Terminated
Early Phase 1
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Start of enrollment: 2016 May 01
Completed
Phase 1
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
ACTIVE_NOT_RECRUITING
PHASE4
Roles: Contact
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Start of enrollment: 2019 Apr 03
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact
Combination Therapy for the Treatment of Diffuse Midline Gliomas Start of enrollment: 2021 Oct 20
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Amar Gajjar, Anita Mahajan, Tejus Bale, Daniel C Bowers, Liz Canan
Journal of the National Comprehensive Cancer Network. 2025-03-01
Relapse-free survival in a pediatric patient with recurrent EZH2-mutant melanoma treated with adjuvant tazemetostat.
Erin E Resch, Stavriani C Makri, Paola Ghanem, Ezra G Baraban, Kenneth J Cohen
NPJ Precision Oncology. 2025-02-21
Phase 2 Trial of Veliparib, Local Irradiation and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma: A Children's Oncology Group Study.
Matthias A Karajannis, Arzu Onar-Thomas, Tong Lin, Patricia A Baxter, Daniel R Boué
Neuro-Oncology. 2024-11-19

Press Mentions

WellSpan Health Announces Cancer Partnership with Johns HopkinsJuly 3rd, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/kenneth-cohen